CN104231193B - 一种pH与氧化还原双敏感的层交联纳米粒及其制备方法和应用 - Google Patents
一种pH与氧化还原双敏感的层交联纳米粒及其制备方法和应用 Download PDFInfo
- Publication number
- CN104231193B CN104231193B CN201410366575.5A CN201410366575A CN104231193B CN 104231193 B CN104231193 B CN 104231193B CN 201410366575 A CN201410366575 A CN 201410366575A CN 104231193 B CN104231193 B CN 104231193B
- Authority
- CN
- China
- Prior art keywords
- layer
- pds
- pcb
- pdpa
- sensitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004132 cross linking Methods 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 75
- 239000002105 nanoparticle Substances 0.000 claims abstract description 75
- 229920000642 polymer Polymers 0.000 claims abstract description 52
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 36
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 19
- 239000002253 acid Substances 0.000 claims abstract description 18
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 201000011510 cancer Diseases 0.000 claims abstract description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 8
- 229960003237 betaine Drugs 0.000 claims abstract description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 4
- NRGGMCIBEHEAIL-UHFFFAOYSA-N 2-ethylpyridine Chemical compound CCC1=CC=CC=N1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 claims abstract description 3
- 150000007513 acids Chemical class 0.000 claims abstract description 3
- 229920001510 poly[2-(diisopropylamino)ethyl methacrylate] polymer Polymers 0.000 claims description 53
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 16
- 238000006116 polymerization reaction Methods 0.000 claims description 15
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229940109262 curcumin Drugs 0.000 claims description 8
- 235000012754 curcumin Nutrition 0.000 claims description 8
- 239000004148 curcumin Substances 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 8
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 8
- PAEZRCINULFAGO-OAQYLSRUSA-N (R)-homocamptothecin Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC=CC=C3N=C21 PAEZRCINULFAGO-OAQYLSRUSA-N 0.000 claims description 7
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 7
- -1 diisopropylaminoethyl ethyl Chemical group 0.000 claims description 7
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- 229940009456 adriamycin Drugs 0.000 claims description 5
- 239000012074 organic phase Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- 229960001561 bleomycin Drugs 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 238000002525 ultrasonication Methods 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract description 52
- 229960003180 glutathione Drugs 0.000 abstract description 27
- 210000004881 tumor cell Anatomy 0.000 abstract description 26
- 235000003969 glutathione Nutrition 0.000 abstract description 8
- 230000012202 endocytosis Effects 0.000 abstract description 6
- 238000010494 dissociation reaction Methods 0.000 abstract description 3
- 230000005593 dissociations Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 239000010410 layer Substances 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 230000008859 change Effects 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000002539 nanocarrier Substances 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 101000687640 Streptomyces caespitosus Extracellular small neutral protease Proteins 0.000 description 7
- 230000000118 anti-neoplastic effect Effects 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 108010024636 Glutathione Proteins 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 4
- 210000001163 endosome Anatomy 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- AISZNMCRXZWVAT-UHFFFAOYSA-N 2-ethylsulfanylcarbothioylsulfanyl-2-methylpropanenitrile Chemical compound CCSC(=S)SC(C)(C)C#N AISZNMCRXZWVAT-UHFFFAOYSA-N 0.000 description 2
- 241001044369 Amphion Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 239000012987 RAFT agent Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 239000013047 polymeric layer Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- KYLIZBIRMBGUOP-UHFFFAOYSA-N Anetholtrithion Chemical group C1=CC(OC)=CC=C1C1=CC(=S)SS1 KYLIZBIRMBGUOP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 0 CC**C1C(CC)CCC*1 Chemical compound CC**C1C(CC)CCC*1 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000012711 chain transfer polymerization Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000006202 diisopropylaminoethyl group Chemical group [H]C([H])([H])C([H])(N(C([H])([H])C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Description
实施例 | 纳米粒 | 聚合物 | 药物/载药量(%) | 粒径(nm) |
14 | II-1 | I-1 | DOX/5.6 | 153 |
15 | II-1b | I-1 | ---- | 142 |
16 | II-2 | I-2 | DOX/5.8 | 150 |
17 | II-3 | I-3 | DOX/5.7 | 152 |
18 | II-4 | I-4 | DOX/5.6 | 152 |
19 | II-5 | I-5 | DOX/5.6 | 155 |
20 | II-6 | I-6 | DOX/5.7 | 150 |
21 | II-7 | I-7 | PTX/15 | 200 |
22 | II-8 | I-7 | CPT/8.9+HCPT/3.1 | 180 |
23 | II-9 | I-8 | HCPT/8.1 | 145 |
24 | II-10 | I-8 | TXT/8.2 | 255 |
25 | II-11 | I-9 | DXM/8.3+CUR/0.6 | 163 |
26 | II-12 | I-9 | CUR/0.9 | 80 |
27 | II-13 | I-10 | CUR/0.5 | 50 |
28 | II-14 | I-10 | BLM/6.5+TXT/2.2 | 130 |
29 | II-15 | I-11 | DXM/6.4 | 149 |
30 | II-16 | I-12 | VLB/1.3 | 170 |
31 | II-17 | I-13 | VLB/0.8 | 210 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410366575.5A CN104231193B (zh) | 2014-07-29 | 2014-07-29 | 一种pH与氧化还原双敏感的层交联纳米粒及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410366575.5A CN104231193B (zh) | 2014-07-29 | 2014-07-29 | 一种pH与氧化还原双敏感的层交联纳米粒及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104231193A CN104231193A (zh) | 2014-12-24 |
CN104231193B true CN104231193B (zh) | 2016-10-05 |
Family
ID=52220170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410366575.5A Active CN104231193B (zh) | 2014-07-29 | 2014-07-29 | 一种pH与氧化还原双敏感的层交联纳米粒及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104231193B (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109069872B (zh) * | 2015-12-09 | 2021-07-13 | 得克萨斯州大学系统董事会 | 用于治疗疾病的聚合物药物递送系统 |
WO2017173453A1 (en) * | 2016-04-01 | 2017-10-05 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
CN105968373B (zh) * | 2016-05-16 | 2019-09-20 | 四川大学 | 一种含两性离子的多重酸敏感抗肿瘤载药胶束及其制备方法和应用 |
CN106265509B (zh) * | 2016-08-10 | 2019-05-07 | 国家纳米科学中心 | 一种pH和Redox双响应两亲性嵌段共聚物及其制备方法和用途 |
CN107617108A (zh) * | 2017-09-14 | 2018-01-23 | 天津工业大学 | 一种双靶向和pH/氧化还原双敏感的核交联纳米粒及其制备方法和应用 |
CN107684628B (zh) * | 2017-11-14 | 2020-05-22 | 中国医学科学院生物医学工程研究所 | 用于巯基检测的氟-19磁共振造影探针的制备方法与应用 |
CN107721888B (zh) * | 2017-11-14 | 2020-04-21 | 中国医学科学院生物医学工程研究所 | 氧化还原诱导pH响应型甲基丙烯酸酯类含氟单体与合成方法和应用 |
CN107823184B (zh) * | 2017-11-14 | 2020-10-23 | 中国医学科学院生物医学工程研究所 | 氧化还原敏感诱导pH响应纳米药物载体的制备方法与应用 |
CN108567765B (zh) * | 2018-06-14 | 2020-04-28 | 中国科学院宁波材料技术与工程研究所 | 一种基于天然多糖的肿瘤微环境双重响应性药物控释微胶囊及其应用 |
CN110938420A (zh) * | 2018-09-21 | 2020-03-31 | 北京大学 | 一种还原响应性荧光探针的结构、制备及应用 |
CN109400830B (zh) * | 2018-10-18 | 2020-11-06 | 合肥工业大学 | 一种pH可解离轻度交联聚合物纳米材料及其制备方法和应用 |
CN109568294B (zh) * | 2018-10-24 | 2021-02-02 | 浙江工业大学 | 两性离子纳米聚合物胶囊的可控制备方法 |
CN110251485A (zh) * | 2019-07-16 | 2019-09-20 | 东南大学 | 一种氧化敏感药物组合物及其制备和应用 |
CN110624113B (zh) * | 2019-08-21 | 2022-11-08 | 山东大学 | 一种靶向聚乙二醇纳米粒子药物载体的超声制备方法与应用 |
CN110702899A (zh) * | 2019-10-12 | 2020-01-17 | 香港大德昌龙生物科技有限公司 | 生物素标记的dna及其制备方法、试剂盒 |
CN110693851B (zh) * | 2019-10-24 | 2022-03-25 | 西安医学院 | 一种介孔二氧化硅载药纳米粒及其制备方法和应用 |
CN111514308B (zh) * | 2020-03-10 | 2023-02-17 | 西南民族大学 | pH诱导电荷翻转型抗菌金纳米棒及其制备方法和应用 |
WO2021226762A1 (zh) * | 2020-05-09 | 2021-11-18 | 王树滨 | 肿瘤微环境响应型纳米复合载药系统及其制备方法和应用 |
CN113549184A (zh) * | 2021-07-23 | 2021-10-26 | 南充市中心医院 | 同时具有pH和氧化还原双响应的聚合物载体、载药胶束及制备方法和应用 |
CN113698556A (zh) * | 2021-08-18 | 2021-11-26 | 新乡医学院 | 一种氧化还原敏感型靶向载药聚合物的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102973488A (zh) * | 2012-12-02 | 2013-03-20 | 复旦大学 | 具有氧化还原/pH双重刺激响应性的纳米水凝胶及其制备方法和应用 |
CN103613716A (zh) * | 2013-11-29 | 2014-03-05 | 西安医学院 | 一种pH-氧化还原双敏感型两亲聚合物及其制备方法 |
-
2014
- 2014-07-29 CN CN201410366575.5A patent/CN104231193B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102973488A (zh) * | 2012-12-02 | 2013-03-20 | 复旦大学 | 具有氧化还原/pH双重刺激响应性的纳米水凝胶及其制备方法和应用 |
CN103613716A (zh) * | 2013-11-29 | 2014-03-05 | 西安医学院 | 一种pH-氧化还原双敏感型两亲聚合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104231193A (zh) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104231193B (zh) | 一种pH与氧化还原双敏感的层交联纳米粒及其制备方法和应用 | |
Hu et al. | pH-responsive and charge shielded cationic micelle of poly (L-histidine)-block-short branched PEI for acidic cancer treatment | |
Tan et al. | A novel MPEG-PDLLA-PLL copolymer for docetaxel delivery in breast cancer therapy | |
Guo et al. | pH-triggered intracellular release from actively targeting polymer micelles | |
Xu et al. | Smart and hyper-fast responsive polyprodrug nanoplatform for targeted cancer therapy | |
Sun et al. | Temperature-sensitive gold nanoparticle-coated pluronic-PLL nanoparticles for drug delivery and chemo-photothermal therapy | |
Huang et al. | Bridging the gap between macroscale drug delivery systems and nanomedicines: a nanoparticle-assembled thermosensitive hydrogel for peritumoral chemotherapy | |
CN105524272B (zh) | 硫辛酸修饰的聚乙二醇-聚氨基酸嵌段共聚物的制备和应用 | |
CN105315455B (zh) | 谷氨酸修饰的聚乙二醇单硬脂酸酯的制备及其在靶向药物传递中的应用 | |
CN105963706B (zh) | 一种支化hpma共聚物-dox偶联物及其制备方法和应用 | |
CN104888235A (zh) | 具有共递送多个药物的pH敏感纳米粒前药及其制备方法与应用 | |
CN103656652B (zh) | 一种双敏感响应型聚合物纳米胶束及其制备方法和应用 | |
CN104530256A (zh) | 透明质酸维生素e琥珀酸酯聚合物及其制备和用途 | |
CN105859990B (zh) | 侧链含硫辛酰基的聚合物、其制备方法及由其制备的聚合物囊泡及其应用 | |
CN107617108A (zh) | 一种双靶向和pH/氧化还原双敏感的核交联纳米粒及其制备方法和应用 | |
Zhang et al. | Zinc finger-inspired nanohydrogels with glutathione/pH triggered degradation based on coordination substitution for highly efficient delivery of anti-cancer drugs | |
Song et al. | pH-Sensitive morphological transitions in polymeric tadpole assemblies for programmed tumor therapy | |
Zhang et al. | Tumor-targeting micelles based on linear–dendritic PEG–PTX8 conjugate for triple negative breast cancer therapy | |
Guo et al. | In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy | |
WO2013181888A1 (zh) | 一种环境响应基础共聚物及其制备方法 | |
CN108245483A (zh) | 一种包载难溶性抗肿瘤药物的聚合物纳米胶束体系 | |
KR100831391B1 (ko) | pH 민감성 이미다졸 그룹을 함유한 키토산 복합체 및 그제조방법 | |
CN108126210A (zh) | 一种单靶向还原响应囊泡纳米药物在制备脑肿瘤治疗药物中的应用 | |
CN107982217A (zh) | 一种包载疏水性药物的具靶向和放疗增敏双重功能脂质-聚合物、其制备方法及其应用 | |
Chen et al. | A dual-targeting nanocarrier based on modified chitosan micelles for tumor imaging and therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210908 Address after: Room 109, no.1866, Bohai 12th Road, Port Economic Zone, Binhai New Area, Tianjin 300452 Patentee after: Tianjin Bohua Xinchuang Technology Co.,Ltd. Address before: 300072 Tianjin City, Nankai District Wei Jin Road No. 92, Tianjin University Patentee before: Tianjin University |
|
TR01 | Transfer of patent right | ||
OL01 | Intention to license declared | ||
OL01 | Intention to license declared | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20141224 Assignee: TIANJIN TIAN YUAN ELECTRICAL MATERIALS CO.,LTD. Assignor: Tianjin Bohua Xinchuang Technology Co.,Ltd. Contract record no.: X2024980003329 Denomination of invention: A pH and redox double sensitive layer crosslinked nanoparticle and its preparation method and application Granted publication date: 20161005 License type: Common License Record date: 20240322 Application publication date: 20141224 Assignee: Tianjin aisida New Material Technology Co.,Ltd. Assignor: Tianjin Bohua Xinchuang Technology Co.,Ltd. Contract record no.: X2024980003325 Denomination of invention: A pH and redox double sensitive layer crosslinked nanoparticle and its preparation method and application Granted publication date: 20161005 License type: Common License Record date: 20240322 |
|
EE01 | Entry into force of recordation of patent licensing contract |